Journal
SCIENCE TRANSLATIONAL MEDICINE
Volume 12, Issue 560, Pages -Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scitranslmed.aau3960
Keywords
-
Categories
Funding
- Luxembourg National Research Fund (FNR) within the PEARL programme (FNR) [FNR/P13/6682797]
- German Research Council (DFG) [KR2119/8-1, KL1134/11-1]
- EU Joint Program-Neurodegenerative Diseases (JPND)
- European Union's Horizon2020 research and innovation program [692320]
- NIH [R01NS076054, R37 NS096241]
- Luxembourg National Research Fund (FNR) [C13/BM/5782168]
- HUPO Brain Proteome Project, PURE (a project of Nordrhein-Westfalen, a federal German state)
- Deutsche Parkinson Gesellschaft e.V.
- Verein zur Durchfuhrung Neurowissenschaftlicher Tagungen e.V. (Berlin, Germany)
- German Science Foundation Collaborative Research Centre (CRC) [CRC 870, WU 164/5-1]
- Munich Cluster for Systems Neurology [EXC 1010]
- Bavarian Ministry of Education, Culture and Science [Human Induced Pluripotent Stem Cells (ForIPS)]
- Helmholtz Portfolio Theme Supercomputing and Modelling for the Human Brain (SMHB)
- German Federal Ministry of Education and Research (BMBF) [031A430E]
- Hermann and Lilly Schilling Foundation
- EU Joint Program-Neurodegenerative Diseases (COURAGE-PD)
- EU Joint Program-Neurodegenerative Diseases (3DPD)
Ask authors/readers for more resources
Parkinson's disease (PD) is a heterogeneous neurodegenerative disorder with monogenic forms representing prototypes of the underlying molecular pathology and reproducing to variable degrees the sporadic forms of the disease. Using a patient-based in vitro model of PARK7-linked PD, we identified a U1-dependent splicing defect causing a drastic reduction in DJ-1 protein and, consequently, mitochondria! dysfunction. Targeting defective exon skipping with genetically engineered U1 -snRNA recovered DJ-1 protein expression in neuronal precursor cells and differentiated neurons. After prioritization of candidate drugs, we identified and validated a combinatorial treatment with the small-molecule compounds rectifier of aberrant splicing (RECTAS) and phenylbutyric acid, which restored DJ-1 protein and mitochondria! dysfunction in patient-derived fibroblasts as well as dopaminergic neuronal cell loss in mutant midbrain organoids. Our analysis of a large number of exomes revealed that U1 splice-site mutations were enriched in sporadic PD patients. Therefore, our study suggests an alternative strategy to restore cellular abnormalities in in vitro models of PD and provides a proof of concept for neuroprotection based on precision medicine strategies in PD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available